Target intelligence / Profile preview

GM2 ganglioside (GM2)

Target
GM2
Molecular classification
Ganglioside, Glycosphingolipid, Sphingolipid
01

Overview

GM2 ganglioside is a sialic acid-containing glycosphingolipid primarily located within the outer leaflet of neuronal plasma membranes, where it plays critical roles in cell signaling and membrane organization (PubChem CID 9835556). Under normal physiological conditions, it is catabolized in the lysosome by the enzyme Beta-hexosaminidase A (Hex A) in conjunction with the GM2 activator protein (UniProt P06865). In individuals with genetic deficiencies in Hex A (Tay-Sachs disease) or the activator protein (AB variant), GM2 ganglioside and related substrates like GA2 accumulate to toxic levels within lysosomes, leading to progressive neurodegeneration and central nervous system dysfunction (NIH GARD). Therapeutic strategies targeting this molecule focus on reducing its synthesis through substrate reduction therapy (SRT) or enhancing its degradation via enzyme replacement therapy (ERT), gene therapy, or pharmacological chaperones. Current drug development efforts, such as those involving venglustat, aim to cross the blood-brain barrier to mitigate the catastrophic neurological impact of GM2 accumulation.

Other names
Monosialotetrahexosylganglioside 2GalNAc-beta1,4-(NeuAc-alpha2,3)-Gal-beta1,4-Glc-ceramideII3-alpha-Neu5Ac-Gg3CerTay-Sachs gangliosideGanglioside G2
02

Mechanism of action

Substrate reduction therapy (SRT) via inhibition of glucosylceramide synthase to decrease GM2 synthesis; Pharmacological chaperone therapy to stabilize mutant Beta-hexosaminidase A; Gene therapy or enzyme replacement to restore lysosomal degradation of GM2.

03

Biological functions

Cell signalingNeuronal membrane organizationCell-cell interactionLysosomal metabolismModulation of growth factor receptors
04

Disease associations

Tay-Sachs diseaseSandhoff diseaseGM2 gangliosidosisAB variant GM2 gangliosidosis
05

Safety considerations

Gastrointestinal distress and weight loss associated with substrate reduction therapyPeripheral neuropathyBlood-brain barrier penetration limitations for large molecule therapiesPotential immunogenicity of recombinant enzymesOff-target inhibition of other glycosidases
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Cerebrospinal fluid GM2 ganglioside levelsPlasma Lyso-GM2Beta-hexosaminidase A activity in leukocytesGM2 activator protein levels

Source types: Trial registry. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on GM2 ganglioside (GM2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GM2 ganglioside (GM2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call